title: The integration of whole abdominal radiotherapy and intraperitoneal cisplatin into the primary management of advanced ovarian carcinoma.
abstract: Eleven women with Stages III and IV epithelial ovarian carcinomas were entered into a protocol consisting of concurrent whole abdominal radiotherapy and intraperitoneal cisplatin followed by additional intraperitoneal cisplatin. The entire abdomen received 20 Gy in 20 fractions with no renal or hepatic shielding. Intraperitoneal cisplatin dosage was 20 mg/m2 weekly during radiation and 90 mg/m2 monthly thereafter for an additional three courses. Patients with Stages IIIC and IV had a median survival of 18 months and a two-year actuarial survival of 32%. Primary failure sites were the abdomen, pleura, and lymph nodes. Acute toxicity during radiotherapy was comparable to patients treated with radiation alone. No chronic renal, hepatic, or enteric complications were observed. Although the protocol did not have substantial efficacy in advanced disease, its toxicity was moderate enough to consider its use in less advanced cancers with peritoneal metastases. In particular, the protocol can be considered for women with ovarian cancer with no gross residuum and for women with papillary serous carcinoma of the uterine corpus.
authors.affiliation: Department of Obstetrics and Gynecology, University of Minnesota Hospital, Minneapolis 55455.
authors.forename: R A
authors.initials: RA
authors.lastname: Potish
authors.forename: L A
authors.initials: LA
authors.lastname: King
authors.forename: G O
authors.initials: GO
authors.lastname: Downey
authors.forename: L L
authors.initials: LL
authors.lastname: Adcock
authors.forename: L F
authors.initials: LF
authors.lastname: Carson
authors.forename: L B
authors.initials: LB
authors.lastname: Twiggs
mesh_terms: D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D002277:Carcinoma / Q000097:blood / Q000401:mortality / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D002985:Clinical Protocols / Q000592:standards*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007274:Injections, Intraperitoneal; D010051:Ovarian Neoplasms / Q000097:blood / Q000401:mortality / Q000628:therapy*; D011878:Radiotherapy / Q000379:methods / Q000592:standards*; D015996:Survival Rate
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D002945:Cisplatin